Search results for "BREAST CARCINOMA"

showing 10 items of 59 documents

Secretory breast carcinoma with metastatic sentinel lymph node

2006

Abstract Background Secretory mammary carcinoma is a rare breast neoplasia originally described in children but sometimes also found in adults. It presents a more favourable outcome than more common histological types of breast carcinoma; published literature in fact reports only a few cases with axillary lymph node metastases and only four cases with distant metastases. Clinical presentation In this paper we report a rare case of secretory breast carcinoma with axillary lymph node metastases in a 33-year-old woman. To our knowledge, this is the first case of secretory carcinoma involving biopsy of the sentinel lymph node and investigation of the e-cadherin expression. We found positivity f…

Oncologymedicine.medical_specialtyPathologySentinel lymph nodelcsh:SurgeryCase ReportSettore MED/08 - Anatomia Patologicalcsh:RC254-282Mammary carcinomasentinel lymph nodeSurgical oncologyInternal medicinemedicineLymph nodebusiness.industrylcsh:RD1-811lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSecretory breast carcinomaSettore MED/18 - Chirurgia GeneraleLymphedemamedicine.anatomical_structureSecretory breast carcinoma; sentinel lymph node; metastases; e-cadherinOncologymetastaseSurgerybusinessBreast carcinomae-cadherinSecretory Breast CarcinomaWorld Journal of Surgical Oncology
researchProduct

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis

2021

A retrospective analysis of 70 patients with triple-negative or hormone-resistant advanced breast carcinoma who had not previously received chemotherapy was carried out. Patients received oral vinorelbine 60 mg/m2 on day 1 and 8, plus capecitabine 1000 mg/m2 bid for 14 consecutive days every 3 weeks. Overall response rate was 53% with a 9% complete response rate. Stable disease was recorded in 27% of the cases. Median progression-free survival was 7.9 months and median overall survival was 29.2 months. Toxicity was generally mild and easily manageable. These data demonstrate that this combination is feasible, safe and active as first-line treatment of triple-negative fully hormone-resistant…

Oncologymedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentVinorelbineCapecitabineStable DiseaseInternal medicineCarcinomamedicinebreast carcinomaoral chemotherapymetastasesChemotherapybusiness.industrycapecitabinemedicine.diseaseMetastatic breast cancervinorelbineSettore MED/18 - Chirurgia GeneraleToxicitybusinessBreast carcinomaBiotechnologymedicine.drugResearch Article
researchProduct

Gene Expression Analyses in Early Breast Carcinoma — Quo Vadis?

2017

AbstractIn order to establish whether adjuvant therapy should be administered in patients with breast carcinoma, it is decisive to have as precise as possible an assessment of the risk of recurrence. In this context, gene expression — and thus gene expression signatures as well — have become a focus of attention as prognostic factors. For practical application, it is important to be able to analyze gene expression signatures in formalin-fixed, paraffin-embedded tumor tissue. Careful analytic and clinical validations and a high level of evidence (LoE) are required in order to avoid imprecise risk classification and thus potential overtreatment or undertreatment of the patients. Among the com…

Oncologymedicine.medical_specialtybusiness.industryConsensus conferenceContext (language use)Evidence-based medicinemedicine.diseaseBreast cancerInternal medicineGene expressionmedicineAdjuvant therapybusinessProspective cohort studyBreast carcinomaSenologie - Zeitschrift für Mammadiagnostik und -therapie
researchProduct

Tissue Polypeptide Antigen in Patients with Breast Cancer and Gynecological Cancer

1984

Abstract The serum concentrations of TPA were determined in 67 patients with primary breast cancer, in 70 patients with metastasizing breast carcinoma and in 20 patients with ovarian cancer of stages III and IV (FIGO). Elevated TPA levels (>85 U/L) were found in 54% of patients with primary breast cancer, in 81% of the cases with disseminated disease and in 86% of patients with an ovarian carcinoma stage III. Preoperative TPA values in patients with primary mammary cancer were found to correlate well with tumor size and axillary lymph node involvement. Perioperative course controls in 10 patients exhibited an increase of TPA serum levels. The observation of the patients with metastasizing b…

Oncologymedicine.medical_specialtybusiness.industryTissue Polypeptide AntigenCA 15-3CancerPerioperativemedicine.diseaseBreast cancerOvarian carcinomaInternal medicinemedicineOvarian cancerbusinessBreast carcinoma
researchProduct

Adhesion, growth and cytoskeletal characteristics of 8701-BC breast carcinoma cells cultured in the presence of type V collagen

1990

Type V collagen is one of the minor components of the extracellular matrix (ECM) whose content is increased in cases of ductal infiltrating carcinomas of the breast. In order to clarify its biological role, we have investigated the effect of this molecule, both as substrate and as soluble factor, on the behaviour of a breast carcinoma cell line (8701-BC) grown in vitro. Cell-collagen adhesion was monitored for 24 h from plating in the absence or presence of serum. The influence of type V collagen on cell growth was followed during 9 days of culture, and the actin-vinculin arrangement was studied by simultaneous fluorescent immuno-staining. The results indicate that type V collagen is not a …

Pathologymedicine.medical_specialtyCell growthBreast NeoplasmsAdhesionBiologyMolecular biologyIn vitroExtracellular matrixCytoskeletal ProteinsCarcinoma Intraductal NoninfiltratingOncologyCell cultureCell AdhesionTumor Cells CulturedmedicineHumansNeoplastic cellCollagenCytoskeletonBreast carcinomaCell DivisionEuropean Journal of Cancer and Clinical Oncology
researchProduct

Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma.

2000

Immunohistochemistry using antibodies to cytokeratin 8 can serve as a valuable diagnostic tool for the differentiation of lobular from ductal carcinomas of the breast. In contrast with ductal carcinomas, which exhibit a peripheral-predominant immunostaining pattern, adjacent tumor cells “molding” to each other, lobular carcinomas exhibit a ring-like perinuclear immunostaining pattern, creating a “bag of marbles” appearance with neighboring tumor cells. This immunostaining pattern is stable even in the tumors that otherwise do not exhibit characteristic histomorphologic features (ie, solid or pleomorphic type of a lobular carcinoma) and tumors that mimic growth patterns characteristic of the…

Pathologymedicine.medical_specialtyLobular carcinomaIntermediate FilamentsBreast NeoplasmsBiologyDiagnosis DifferentialImmunoenzyme TechniquesCytokeratinBreast cancerCarcinomamedicineHumansskin and connective tissue diseasesCell NucleusCarcinoma Ductal BreastGeneral MedicineDuctal carcinomamedicine.diseaseCadherinsDuctal Breast CarcinomaCarcinoma LobularInvasive lobular carcinomaKeratin 8KeratinsFemaleAmerican journal of clinical pathology
researchProduct

Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with…

1995

Mutations of the p53 gene often result in the overexpression of p53 protein. Previous studies have suggested that the function of p53 and its mutant protein forms may be linked with the disease course of patients with a breast carcinoma. In the present study, we tested 462 primary breast carcinomas for the presence of p53 antigen using immunohistochemical methods employing antibodies against the clone, DO-1. These tumors were also immunohistochemically stained using the monoclonal antibody, MIB-1, in order to demonstrate the presence of Ki67. Comparison of the presence of p53 with other prognostic parameters revealed highly significant negative correlations with estrogen- and progesterone-r…

Pathologymedicine.medical_specialtyMammary glandBreast NeoplasmsDisease-Free SurvivalAntigenmedicineCarcinomaBiomarkers TumorHumansProliferation MarkerCell NucleusEpitheliomabiologybusiness.industryObstetrics and GynecologyAntibodies Monoclonalmedicine.diseasePrognosisImmunohistochemistrySurvival Analysismedicine.anatomical_structureOncologyMutationCancer researchbiology.proteinImmunohistochemistryRegression AnalysisFemaleAntibodyTumor Suppressor Protein p53Breast carcinomabusinessCell DivisionGynecologic oncology
researchProduct

Immunohistochemical Detection of Hormone Receptors in Breast Carcinomas (ER-ICA, PgR-ICA): Prognostic Usefulness and Comparison with the Biochemical …

1994

In a prospective study conducted since 1983, the hormone-receptor status of primary breast carcinomas was investigated using immunohistochemical (ER-ICA, PgR-ICA) and biochemical (DCC) methods. The degree of immunohistochemical staining was evaluated according to the immunoreactive score (IRS) devised by Remmele and Stegner [Frauenarzt 28, 41-43 (1987)]. The findings obtained using the biochemical radioactive-ligand-binding assay (cutoff level, 20 fmol/mg) and those obtained using qualitative immunohistochemical methods were in agreement in 72.5% (ER-ICA) and 72.2% (PgR-ICA) of cases. For the 789 cases of primary breast carcinoma examined, postoperative data were available for a mean follow…

Pathologymedicine.medical_specialtyMammary glandBreast NeoplasmsRadioligand AssayPredictive Value of TestsCarcinomaHumansMedicineProspective StudiesSurvival analysisProportional Hazards ModelsEpitheliomabusiness.industryObstetrics and GynecologyPrognosismedicine.diseaseSurvival Analysismedicine.anatomical_structureReceptors EstrogenOncologyHormone receptorPredictive value of testsImmunohistochemistryFemaleReceptors ProgesteronebusinessBreast carcinomaGynecologic Oncology
researchProduct

C-erbB-2-oncogene expression in breast carcinoma: Analysis by S1 nuclease protection assay and immunohistochemistry in relation to clinical parameters

1992

The c-erbB-2 mRNA was detected by the S1 nuclease protection assay and Northern blotting in breast cancer tissues. In contrast to the Northern blot analysis which has been used in all recent publications concerning c-erbB-2 expression on the level of RNA, the S1-nuclease protection assay has distinct advantages with respect to sensitivity, reproducibility, and handling of radioactive probes. We compared the expression of c-erbB-2 in 120 breast carcinomas which were operated in the years 1989-1990 on the level of the mRNA (S1 nuclease protection assay) and the protein (immunohistochemistry), respectively. In general, results obtained with both methods were in good agreement. Only minor diffe…

Pathologymedicine.medical_specialtyReceptor ErbB-2Breast NeoplasmsBiologyGene Expression Regulation EnzymologicImmunoenzyme TechniquesBreast cancerProto-Oncogene ProteinsGene expressionmedicineHumansRNA NeoplasmNorthern blotskin and connective tissue diseasesLymph nodeOncogeneSingle-Strand Specific DNA and RNA EndonucleasesObstetrics and GynecologyBlotting Northernmedicine.diseaseSurvival AnalysisGene Expression Regulation NeoplasticBlotmedicine.anatomical_structureOncologyCancer researchImmunohistochemistryFemaleBreast carcinomaGynecologic Oncology
researchProduct

Validity of needle core biopsy in the histological characterisation of mammary lesions

2006

Summary Over the last few years, there has been an enormous increase in the use of needle core biopsy (CB) for the histopathological characterisation of suspect lesions of the breast. The aim of this study was to verify the diagnostic reliability of CB by comparing the histological results obtained with the use of this technique with those obtained from the whole of the surgically resected specimen. We studied 198 out of 426 patients with clinically and/or radiologically suspect breast lesions. We found correspondence between the histological examination of the whole of the excised specimen and that of the CB in 94.9% of the cases of infiltrating carcinoma and in 71.4% of those involving du…

Pathologymedicine.medical_specialtyReproducibility of ResultBreast NeoplasmsSensitivity and SpecificityBreast cancerNeedle core biopsyRetrospective StudiemedicineCarcinomaHumansbreast carcinomahumanintermethod comparisonarticle; breast carcinoma; breast disease; carcinoma in situ; diagnostic accuracy; diagnostic value; histopathology; human; human tissue; intermethod comparison; intraductal carcinoma; major clinical study; needle biopsy; prediction; priority journal; reliability; sensitivity and specificity; validation process Biopsy Needle; Breast Neoplasms; Carcinoma Ductal Breast; Carcinoma Intraductal Noninfiltrating; Female; Humans; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity [EMTREE medical terms]Retrospective Studiesintraductal carcinomaHistological examinationreliabilitybusiness.industryBiopsy Needlevalidation process MeSH: Biopsy NeedleCarcinoma Ductal Breastbreast diseaseReproducibility of Resultscarcinoma in situneedle biopsypredictionGeneral Medicinemedicine.diseasemajor clinical studyPredictive valuehuman tissueCarcinoma Intraductal Noninfiltratingpriority journalhistopathologyEMTREE medical terms: articlediagnostic accuracyFemaleSurgerydiagnostic valueRadiologybusinessCore biopsyBreast NeoplasmThe Breast
researchProduct